Looks like Prurisol will take a back seat because they have documented efficacy in the Kevetrin trial at Dana Farber. It makes sense to focus on this critical trial of the first in class p53 activating oncology drug with little or no toxicity !!!
If you look at the slides and read them carefully, it appears that at least one patient was down staged while on Kevetrin indicating tumor shrinkage.
Coincidence or efficacy ?
One must listen to the conference call to understand. .
Market Data 
Markets 
AI
